Current status and perspectives of Clonorchis sinensis and clonorchiasis: epidemiology, pathogenesis, omics, prevention and control

Table 1 Therapeutic schemes and drugs for clonorchiasis

Therapeutic regimen		Disease information	Treatment effect	References
Praziquantel	Orally, 18.8 mg/kg twice daily for 2 days.	Co-infection with other helminthes.	CR: 56.8 % (1st, 21/37), 75 % (2nd, 12/16).	[53]
	Orally, 25 mg/kg three times for 1 day.	No other illness.	CR: 56 % (14/25).	[54]
	Orally, 25 mg/kg for three times.	No other illness.	CR: 62.9 %(83/132),	[55]
	Orally, 3.6 g/d three times daily for 2 days, combined with ENBD.	Severe infection, jaundice.	Effective and safe.	[56]
SRP	Orally, 30 mg/kg once.	Severe infection.	CR: 60 % (12/20), side effects.	[57]
Tribendimidine	Orally, 400 mg once.	Co-infection with other helminthes.	CR: 50 % (1st, 17/34), 78.1 % (2nd, 25/32).	[53]
	Orally, 200 mg twice for 1 day.	Co-infection with other helminthes.	CR: 33.3 % (11/33).	[53]
	Orally, 400 mg once.	No other illness.	CR: 44 % (11/25).	[54]
Mebendazole	Orally, 400 mg once.	Co-infection with other helminthes.	CR: 0 % (0/30)	[53]

CR cure rate, ENBD endoscopic nasobiliary drainage, SRP sustained-releasing praziquantel, 1st the first treatment, 2nd the second treatment

ISSN: 2049-9957